Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd (ADXN) filed a routine Form 6-K on 20 June 2025. The filing primarily serves two administrative purposes: (1) it makes available unaudited interim condensed consolidated financial statements, management’s discussion and analysis (MD&A), and a 19 June 2025 press release as Exhibits 99.1-99.3; and (2) it formally incorporates those exhibits by reference into the company’s existing shelf registration statement on Form F-3 (No. 333-255089) and employee share-plan registration statements on Form S-8 (Nos. 333-255124 and 333-272515).
The company re-iterates that investors should review the risk factors detailed in its Form 20-F for the year ended 31 December 2024, filed 15 May 2025, and cautions that forward-looking statements remain subject to those risks. No new financial metrics, guidance, or transactional announcements are included in this 6-K.
CEO Tim Dyer signed the report on behalf of the registrant.